XVIVO opens a subsidiary in Australia

Based on the increasing interest for XVIVO Perfusion´s products for lung transplantation as well as the high interest from all Australian clinics to participate in the Heart preservation study XVIVO Perfusion AB (publ) has decided to open a subsidiary in Sydney, Australia.   XVIVO also recently hired a Regional Business Manager with start date in October 2019.

Currently XVIVO has two XPS-systems installed in the Pacific region and during the year the company noted an increasing interest from all five Lung transplant clinics to purchase an XPS. During the summer all heart transplant clinics in Australia reported a high interest to participate in the planned clinical study with XVIVOs products for heart preservation. Today, around four hours of preservation time is possible for a donated heart. Based on the stretched distances in Australia longer preservation time will enable improved matching of donated hearts. XVIVO´s products for heart preservation have pre-clinically showed that 24 hours of preservation time is possible.

To support both the increasing interest for EVLP (Ex Vivo Lung Perfusion) with XPS and STEEN Solution as well as XVIVO´s heart preservation technology the company has decided to employ a Regional Business and Technical manager for the Pacific region (Australia & New Zealand). Physical presence in the Pacific region will enable closer contact with the clinics and quick support if needed.

“We are pleased to see both an increasing interest for the XPS and STEEN Solution and for XVIVO´s clinical heart preservation study, from the Pacific region. With our presence in Australia the last threshold for growth has been removed,” said Dr. Magnus Nilsson, Chief Executive Officer of XVIVO Perfusion.

October 23, 2019
Magnus Nilsson
Gothenburg
XVIVO Perfusion AB (publ)

For further information please contact:

Christoffer Rosenblad, CFO, +46 735 192159, christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com

The information was submitted for publication, through the agency of the contact person set out above, at 4:00 pm CET on October 23, 2019.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.